Avalon Ventures XI Adjusts Janux Therapeutics Stake

TL;DR

Avalon Ventures XI filed a 13D/A for Janux Therapeutics, Inc. - stake adjusted.

AI Summary

On March 4, 2024, Avalon Ventures XI, L.P. filed an amendment to its Schedule 13D, reporting a change in beneficial ownership of Janux Therapeutics, Inc. The filing indicates a shift in holdings, though specific dollar amounts and exact percentage changes are not detailed in this excerpt. The amendment was filed under the Securities Exchange Act of 1934.

Why It Matters

This filing signals a potential shift in control or investment strategy by a significant shareholder in Janux Therapeutics, which could influence the company's stock performance and future direction.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant changes in ownership by major investors, which can lead to increased volatility.

Key Players & Entities

• Avalon Ventures XI, L.P. (company) — Filing entity
• Janux Therapeutics, Inc. (company) — Subject company
• ABV SPV I GP LLC (company) — Group member
• AVALON BIOVENTURES GP, LLC (company) — Group member
• AVALON BIOVENTURES I, LP (company) — Group member
• AVALON BIOVENTURES SPV I, L.P. (company) — Group member
• AVALON VENTURES XI GP LLC (company) — Group member
• BRADEN BOHRMANN (person) — Group member
• JAY LICHTER, PH.D. (person) — Group member
• KEVIN KINSELLA (person) — Group member

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 47103
• $45.37 — on Stock at a weighted average price of $45.37 per share in multiple open market trans
• $45.00 — ket transactions at prices ranging from $45.00 to $45.38 inclusive. On March 2, 2024,
• $45.38 — ctions at prices ranging from $45.00 to $45.38 inclusive. On March 2, 2024, Madigan s
• $45.67 — on Stock at a weighted average price of $45.67 per share in multiple open market trans
• $46.37 — ctions at prices ranging from $45.00 to $46.37 inclusive. 15 Item 5. Interest in Se

Filing Documents

• tm247915d1_sc13da.htm (SC 13D/A) — 228KB
• tm247915d1_ex99a.htm (EX-99.A) — 10KB
• 0001104659-24-030638.txt ( ) — 240KB

Purpose of Transaction

Item 4. Purpose of Transaction

of the Original Schedule 13D is hereby amended and supplemented

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraphs at the end of Item 4: On February 29, 2024, Avalon Ventures made a pro rata in-kind distribution for no additional consideration of an aggregate of 438,722 shares of Common Stock to its general partner and limited partners. Of the shares distributed by Avalon Ventures, Avalon XI GP received 11,388 shares. On February 29, 2024, ABV SVP made a pro rata in-kind distribution for no additional consideration of an aggregate of 447,949 shares of Common Stock to its general partner and limited partners. Of the shares distributed by ABV SPV, ABV SPV GP received 31,456 shares. On February 29, 2024, ABV I made a pro rata in-kind distribution for no additional consideration of an aggregate of 84,985 shares of Common Stock to its general partner and limited partners. Of the shares distributed by ABV I, ABV GP and Kinsella received 1,700 and 319 shares, respectively. On February 29, 2024, ABV XI GP made a pro rata in-kind distribution for no additional consideration of an aggregate of 11,388 shares of Common Stock to its members. Of the shares distributed by ABV XI GP, Kinsella, Levandov, Bohrmann, Lichter and Reardon received 3,163; 3,163; 1,265; 3,163 and 634 shares, respectively. On February 29, 2024, ABV SPV GP made a pro rata in-kind distribution for no additional consideration of an aggregate of 31,456 shares of Common Stock to its members. Of the shares distributed by ABV SPV GP, Kinsella, Levandov, Bohrmann, Lichter, Reardon and Madigan received 3,484; 2,488; 2,489; 995; 995; and 1,493 shares respectively. On February 29, 2024, ABV GP made a pro rata in-kind distribution for no additional consideration of an aggregate of 1,700 shares of Common Stock to its members. Of the shares distributed by ABV GP, Lichter, Reardon, Duron and Madigan received 425; 425; 425; and 425 shares respectively. On March 2, 2024, Duron sold 12,343 shares of Common Stock at a weighted

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer (a)– (b). The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of March 4, 2024: Reporting Persons Shares Held Directly Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Beneficial Percentage of Class (6) Avalon Ventures (1) 3,948,495 3,948,495 3,948,495 3,948,495 7.7 % ABV SPV (2) 4,031,543 4,031,543 4,031,543 4,031,543 7.8 % ABV I

View Full Filing

View this SC 13D/A filing on SEC EDGAR